

## **Preceyes and Mount Sinai enter into strategic collaboration**

**Eindhoven, the Netherlands, January 21, 2021 –Preceyes B.V. (NL) and the Mount Sinai Health System (US) have entered into a long-term strategic collaboration with the anticipated aim of further developing robot-assisted ocular surgical procedures. As part of the collaboration, Mount Sinai has made an equity investment in Preceyes and joins its Board of Directors. This collaboration will also support Preceyes’ strategy to enter the US market following the FDA approvals and clearance process.**

The collaboration and equity investment follows the arrival of an investigational PRECEYES Surgical System at New York Eye and Ear Infirmary of Mount Sinai (NYEE) in June 2020, the first installation of a medical robot for ophthalmology in the United States. The PRECEYES Surgical System is not yet approved for use in the United States. NYEE is currently using the installed robot to perform laboratory research, explore possible future clinical uses and introduce the technology to NYEE researchers. Preceyes and Mount Sinai plan to collaborate to further develop ocular surgical procedures that will enable novel high-precision treatments and benefit existing surgical procedures, and eventually to develop and launch the first clinical studies of this exciting technology in the United States. Combining a rich history of specialty care with award-winning clinical excellence, training and education, NYEE will be a potential key partner in FDA-guided clinical trials.

Gerrit Naus, co-founder and Chief Executive Officer of Preceyes said: “The collaboration with Mount Sinai is a major recognition of our technology’s potential impact on ocular surgery and our company’s unique position in the field of high-precision medical robotics. We are delighted to have Mount Sinai as a partner as we grow Preceyes into a leading medical robotics company by serving our customers in their care of patients. Mount Sinai’s investment and partnership form a key milestone that supports our long-term strategy.”

Sean Ianchulev, Professor of Ophthalmology and Head of the Microsurgical Robotics Program at NYEE said: “Our faculty and leadership at Mount Sinai work relentlessly to bring better care to our patients. It is nothing less than remarkable that, amid a pandemic, NYEE continues to innovate, leading the way to the future in surgical robotics for ophthalmic care in the US.”

The PRECEYES Surgical System is the world’s first CE-marked robotic system that has been clinically validated to assist surgeons in retinal surgery. The system is not yet approved for use in the United States. The system is intended to assist trained surgeons during retina surgery in patients requiring vitreoretinal intervention under local or general anesthesia. The use of the robotic assistant is anticipated to not only improve treatment quality to be provided to patients, but also offers the possibility of developing completely new treatments. The system has a proprietary design and is developed in collaboration with clinicians to user requirements.

### **Further information**

**Preceyes:** Gerrit Naus, Chief Executive Officer of Preceyes B.V., +31402474789, [contact@preceyes.nl](mailto:contact@preceyes.nl), [www.preceyes.nl](http://www.preceyes.nl).

### **About Preceyes B.V.**

Preceyes is a medical robotics company focused on ocular surgery. The company develops, builds and commercializes innovative robotic solutions to assist eye surgeons in performing the most

demanding surgical tasks. The company has a CE-marked product for its first target vitreoretinal surgery. The robot supports the surgeon in improving existing surgery and enables the development of new, high-precision treatments. Preceyes' vision is to transition eye surgery to its next evolution where robotics enables novel therapies, standardizes and improves surgical performance, and provides significant cost-saving by shifting the surgical suite to an office-based setting.

For more information, visit [www.preceyes.nl](http://www.preceyes.nl).

### **About the Mount Sinai Health System**

The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on *U.S. News & World Report's* "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by *U.S. News & World Report*.

For more information, visit <https://www.mountsinai.org> or find Mount Sinai on [Facebook](#), [Twitter](#) and [YouTube](#).